

V. Balasubramanian

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003

V. Balasubramanian

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:17:12 ON 14 MAY 2003 ✓

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:17:18 ON 14 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT -(C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAY 2003 HIGHEST RN 514787-08-7

DICTIONARY FILE UPDATES: 13 MAY 2003 HIGHEST RN 514787-08-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\STNEXP4\QUERIES\10070360.str

L1 STRUCTURE UPLOADED

=> que L1

10/070,360


V. Balasubramanian

L2 QUE L1

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 18:17:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 38 TO ITERATE

100.0% PROCESSED 38 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 391 TO 1129

PROJECTED ANSWERS: 1 TO 80

L3 1 SEA SSS SAM L1


=> d scan

L3 1 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 4-Pyridinecarboxamide, N-[4-methyl-3-[[6-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-4-pyrimidinyl]amino]phenyl]-2-(4-morpholinyl)-(9CI)

MF C28 H34 N8 O3

V. Balasubramanian



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful
FULL SEARCH INITIATED 18:17:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 871 TO ITERATE

100.0% PROCESSED - 871 ITERATIONS -95 ANSWERS
SEARCH TIME: 00.00.01

L4 95 SEA SSS FUL L1

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CAPLUS' ENTERED AT 18:18:02 ON 14 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 May 2003 VOL 138 ISS 20
FILE LAST UPDATED: 13 May 2003 (20030513/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

10/070,360

V. Balasubramanian


=> s 14

L5 4 L4

=> d 15 1-4 bib hitstr

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 2001:283933 CAPLUS
DN 134:295834
TI Preparation of 4-anilinopyrimidines as p38 kinase inhibitors
IN Cumming, John Graham
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001027089	A1	20010419	WO 2000-GB3929	20001010
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	BR 2000014596	A	20020611	BR 2000-14596	20001010
	EP 1226126	A1	20020731	EP 2000-968084	20001010
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003511442	T2	20030325	JP 2001-530109	20001010
	NO 2002001728	A	20020612	NO 2002-1728	20020412
PRAI	GB 1999-24092	A	19991013		
	WO 2000-GB3929	W	20001010		
OS	MARPAT 134:295834				
IT	334893-09-3P 334893-10-6P 334893-17-3P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of 4-anilinopyrimidines as p38 kinase inhibitors)				
RN	334893-09-3 CAPLUS				
CN	Benzamide, N-[3-[(6-chloro-4-pyrimidinyl)amino]-4-methylphenyl]-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)				




RN 334893-10-6 CAPLUS

10/070,360


V. Balasubramanian

CN Benzamide, N-[3-[(6-chloro-4-pyrimidinyl)amino]-4-methylphenyl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 334893-17-3 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[(6-chloro-4-pyrimidinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




IT 334893-08-2P 334893-13-9P 334893-14-0P
334893-15-1P 334893-55-9P 334893-56-0P
334893-57-1P 334893-58-2P 334893-59-3P
334893-60-6P 334893-61-7P 334893-62-8P
334893-63-9P 334893-64-0P 334893-65-1P
334899-56-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-anilinopyrimidines as p38 kinase inhibitors)

RN 334893-08-2 CAPLUS


CN Benzamide, N-[3-[(6-chloro-4-pyrimidinyl)amino]-4-methylphenyl]-3-fluoro-5-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 334893-13-9 CAPLUS


CN Benzamide, N-[3-[(5-amino-6-chloro-4-pyrimidinyl)amino]-4-methylphenyl]-3-fluoro-5-(4-morpholinyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 334893-14-0 CAPLUS

CN Benzamide, N-[4-methyl-3-(4-pyrimidinylamino)phenyl]-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 334893-15-1 CAPLUS

CN Benzamide, 3-(dimethylamino)-N-[4-methyl-3-[[6-[[3-(1-pyrrolidinyl)propyl]amino]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 334893-55-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-methyl-3-[[6-[methyl(1-methyl-4-piperidinyl)amino]-4-pyrimidinyl]amino]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 334893-56-0 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[(1-ethyl-3-piperidinyl)amino]-4-pyrimidinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 334893-57-1 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 334893-58-2 CAPLUS


CN 4-Pyridinecarboxamide, N-[4-methyl-3-[[6-[[3-(4-methyl-1-piperazinyl)propyl]amino]-4-pyrimidinyl]amino]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 334893-59-3 CAPLUS


CN 4-Pyridinecarboxamide, N-[4-methyl-3-[[6-[methyl[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]amino]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 334893-60-6 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-methyl-3-[[6-[[3-(1-pyrrolidinyl)propyl]amino]-4-pyrimidinyl]amino]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 334893-61-7 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[[4-(dimethylamino)butyl]amino]-4-pyrimidinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 334893-62-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-4-pyrimidinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 334893-63-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[[3-(diethylamino)propyl]amino]-4-


V. Balasubramanian

pyrimidinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 334893-64-0 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[[3-(dimethylamino)propyl]amino]-4-pyrimidinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 334893-65-1 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-methyl-3-[[6-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-4-pyrimidinyl]amino]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 334899-56-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-methyl-3-(4-pyrimidinylamino)phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/070,360

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:688241 CAPLUS
 DN 133:252455
 TI Preparation of pyridine and pyrimidine derivatives as inhibitors of
 cytokine mediated disease
 IN Cumming, John Graham
 PA Astrazeneca Ab, Swed.
 SO PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056738	A1	20000928	WO 2000-GB1006	20000317
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	NZ 514042	A	20010928	NZ 2000-514042	20000317
	BR 2000009223	A	20011226	BR 2000-9223	20000317
	EP 1165566	A1	20020102	EP 2000-912750	20000317
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2002540112	T2	20021126	JP 2000-606599	20000317
	NO 2001004589	A	20011121	NO 2001-4589	20010921
PRAI	GB 1999-6566	A	19990323		
	WO 2000-GB1006	W	20000317		

OS MARPAT 133:252455


IT 295776-70-4P 295776-71-5P 295776-72-6P
 295776-73-7P 295776-74-8P 295776-75-9P
 295776-76-0P 295776-77-1P 295776-78-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyridine and pyrimidine derivs. as inhibitors of cytokine mediated disease)

RN 295776-70-4 CAPLUS


CN 4-Pyridinecarboxamide, N-[4-methyl-3-(thieno[3,2-d]pyrimidin-4-ylamino)phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 295776-71-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-methyl-3-[(5-methylthieno[2,3-d]pyrimidin-4-yl)amino]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 295776-72-6 CAPLUS


CN 4-Pyridinecarboxamide, N-[4-methyl-3-[(7-methylthieno[3,2-d]pyrimidin-4-yl)amino]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 295776-73-7 CAPLUS


CN 4-Pyridinecarboxamide, N-[4-methyl-3-(thieno[2,3-d]pyrimidin-4-ylamino)phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 295776-74-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-methyl-3-[[2-(methylthio)thiazolo[5,4-d]pyrimidin-7-yl]amino]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 295776-75-9 CAPLUS


CN 4-Pyridinecarboxamide, N-[4-methyl-3-(pyrido[4,3-d]pyrimidin-4-ylamino)phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 295776-76-0 CAPLUS


CN 4-Pyridinecarboxamide, N-[4-methyl-3-(pyrido[2,3-d]pyrimidin-4-ylamino)phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 295776-77-1 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-methyl-3-(4-pteridinylamino)phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 295776-78-2 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-methyl-3-(1H-purin-6-ylamino)phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 2000:241203 CAPLUS


10/070,360

V. Balasubramanian

DN 132:265207
TI Preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors
of cytokine mediated disease
IN Cumming, John Graham
PA Zeneca Limited, UK
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000020402	A1	20000413	WO 1999-GB3220	19990927
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2341374	AA	20000413	CA 1999-2341374	19990927
	AU 9961064	A1	20000426	AU 1999-61064	19990927
	BR 9914162	A	20010626	BR 1999-14162	19990927
	EP 1117653	A1	20010725	EP 1999-947686	19990927
	EP 1117653	B1	20030205		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, FT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002526538	T2	20020820	JP 2000-574519	19990927
	AT 232205	E	20030215	AT 1999-947686	19990927
	NO 2001001631	A	20010521	NO 2001-1631	20010330
PRAI	GB 1998-21338	A	19981001		
	GB 1999-6564	A	19990323		
	WO 1999-GB3220	W	19990927		
OS	MARPAT 132:265207				
IT	263400-17-5P 263400-18-6P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(prepn. of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)				
RN	263400-17-5 CAPLUS				
CN	4-Pyridinecarboxamide, N-[3-[[6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)				


V. Balasubramanian



● 2 HCl

RN 263400-18-6 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[(6-hydroxy-7-methoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



IT 263399-67-3P 263399-68-4P 263399-70-8P
263399-71-9P 263399-72-0P 263399-74-2P
263399-75-3P 263399-76-4P 263399-77-5P
263399-78-6P 263399-79-7P 263399-87-7P
263399-88-8P 263399-89-9P 263399-90-2P
263399-91-3P 263399-93-5P 263399-94-6P
263399-95-7P 263399-96-8P 263399-97-9P
263399-98-0P 263399-99-1P 263400-00-6P
263400-01-7P 263400-03-9P 263400-04-0P
263400-05-1P 263400-11-9P 263400-12-0P
263400-13-1P 263400-19-7P 263400-20-0P
263400-21-1P 263400-22-2P 263400-23-3P
263400-25-5P 263400-26-6P 263400-27-7P
263400-28-8P 263400-29-9P 263400-30-2P
263400-31-3P 263400-32-4P 263400-33-5P
263400-34-6P 263400-35-7P 263400-36-8P
263400-37-9P 263400-38-0P 263400-39-1P
263400-40-4P 263400-41-5P 263400-42-6P
263400-43-7P 263400-44-8P 263400-45-9P
263400-46-0P 263400-51-7P 263400-52-8P

V. Balasubramanian


263400-53-9P 263400-94-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)

RN 263399-67-3 CAPLUS


CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-68-4 CAPLUS

CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,4-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-70-8 CAPLUS

CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● HCl

RN 263399-71-9 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-72-0 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● HCl

RN 263399-74-2 CAPLUS

CN Benzamide, 4-cyano-N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-75-3 CAPLUS

CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● 2 HCl

RN 263399-76-4 CAPLUS

CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-77-5 CAPLUS

CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● 2 HCl

RN 263399-78-6 CAPLUS

CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-79-7 CAPLUS


CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-3-(dimethylamino)-, dihydrochloride (9CI) (CA INDEX NAME)

V. Balasubramanian



● 2 HCl


RN 263399-87-7 CAPLUS
CN Benzamide, N-[2-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-fluorophenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263399-88-8 CAPLUS
CN 2-Furancarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

V. Balasubramanian



● HCl


RN 263399-89-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 263399-90-2 CAPLUS
CN 5-Isioxazolecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● HCl

RN 263399-91-3 CAPLUS


CN Benzamide, 3-(dimethylamino)-N-[4-methyl-3-[(6,7,8-trimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 263399-93-5 CAPLUS

CN Benzamide, 4-cyano-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● HCl

RN 263399-94-6 CAPLUS


CN Benzamide, N-[2-fluoro-5-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 263399-95-7 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● HCl

RN 263399-96-8 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-97-9 CAPLUS

CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● HCl

RN 263399-98-0 CAPLUS

CN Benzamide, 4-cyano-N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263399-99-1 CAPLUS

CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-cyano-, monohydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● HCl

RN 263400-00-6 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-01-7 CAPLUS

CN Benzamide, N-[4-chloro-3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● HCl

RN 263400-03-9 CAPLUS

CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2,4-difluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-04-0 CAPLUS

CN Benzamide, N-[4-chloro-5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]-3-(dimethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● HCl

RN 263400-05-1 CAPLUS

CN Benzamide, 3-(dimethylamino)-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-11-9 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● 2 HCl

RN 263400-12-0 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-13-1 CAPLUS

CN Benzamide, N-[2-fluoro-5-[(6,7,8-trimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● HCl

RN 263400-19-7 CAPLUS


CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(diethylamino)-2-oxoethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-20-0 CAPLUS


CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)-2-oxoethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 263400-21-1 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)ethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-22-2 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(diethylamino)ethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-23-3 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-[bis(1-methylethyl)amino]ethoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI)


V. Balasubramanian

(CA INDEX NAME)




RN 263400-25-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-[3-(dimethylamino)propoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-26-6 CAPLUS


CN 4-Pyridinecarboxamide, N-[3-[[6-[3-(diethylamino)propoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-27-7 CAPLUS


V. Balasubramanian

CN 4-Pyridinecarboxamide, N-[3-[[6-[2-(dimethylamino)-2-methylpropoxy]-7-methoxy-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI)
(CA INDEX NAME)




RN 263400-28-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-29-9 CAPLUS


CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-piperidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 263400-30-2 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-31-3 CAPLUS


CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-32-4 CAPLUS


CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 263400-33-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-34-6 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 263400-35-7 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[(1-methyl-2-


V. Balasubramanian

piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-(9CI) (CA INDEX NAME)




RN 263400-36-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[(1-methyl-3-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-(9CI) (CA INDEX NAME)



RN 263400-37-9 CAPLUS


CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[(1-methyl-5-oxo-2-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-(9CI) (CA INDEX NAME)



V. Balasubramanian


RN 263400-38-0 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[7-methoxy-6-[2-(2-oxo-1-imidazolidinyl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-39-1 CAPLUS


CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-40-4 CAPLUS


CN Benzamide, 4-cyano-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 263400-41-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-42-6 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[(7-fluoro-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




2 HCl

V. Balasubramanian


RN 263400-43-7 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[3-(methylsulfonyl)propoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-44-8 CAPLUS

CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-45-9 CAPLUS

CN 2-Thiophenecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



● HCl

RN 263400-46-0 CAPLUS

CN Cyclopropanecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]-4-methylphenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263400-51-7 CAPLUS


CN Benzamide, 4-cyano-N-[3-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 263400-52-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-53-9 CAPLUS


CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-94-8 CAPLUS

CN Benzamide, N-[5-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-fluorophenyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian




IT 263400-86-8P 263400-87-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)


RN 263400-86-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[(7-hydroxy-6-methoxy-4-quinazolinyl)amino]-4-methylphenyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 263400-87-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-4-methylphenyl]-2-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1994:217715 CAPLUS
DN 120:217715
TI Quinazoline tyrosine kinase-inhibiting anticancer agents
IN Barker, Andrew J.
PA Zeneca Ltd., UK
SO Can. Pat. Appl., 99 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2086968	AA	19930721	CA 1993-2086968	19930108
	CA 2086968	C	19980623		
	ZA 9300015	A	19930720	ZA 1993-15	19930104
	AU 9331010	A1	19930722	AU 1993-31010	19930104
	AU 661533	B2	19950727		
	HU 63153	A2	19930728	HU 1993-94	19930115
	EP 566226	A1	19931020	EP 1993-300270	19930115
	EP 566226	B1	19951108		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 130000	E	19951115	AT 1993-300270	19930115
	ES 2078798	T3	19951216	ES 1993-300270	19930115
	CZ 282038	B6	19970416	CZ 1993-43	19930118
	NO 9300178	A	19930721	NO 1993-178	19930119
	RU 2127263	C1	19990310	RU 1993-4423	19930119
	SK 281551	B6	20010510	SK 1993-16	19930119
	IL 104479	A1	19991222	IL 1993-104479	19930121
	JP 06073025	A2	19940315	JP 1993-26577	19930216
	JP 2994165	B2	19991227		
	US 5457105	A	19951010	US 1994-284293	19940802
	US 5616582	A	19970401	US 1995-490666	19950615
PRAI	GB 1992-1095	A	19920120		
	GB 1992-13572	A	19920626		
	GB 1992-23735	A	19921112		

V. Balasubramanian

US 1993-5280 B1 19930119
US 1994-284293 A1 19940802
OS MARPAT 120:217715
IT **153437-75-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of, as tyrosine kinase-inhibiting anticancer agent)
RN 153437-75-3 CAPLUS
CN Benzamide, N-[3-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA
INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

12.93

161.29

STN INTERNATIONAL LOGOFF AT 18:18:34 ON 14 MAY 2003